| Literature DB >> 29899446 |
Norio Chihara1, Asaf Madi1,2, Takaaki Kondo1, Huiyuan Zhang1, Nandini Acharya1, Meromit Singer2, Jackson Nyman2, Nemanja D Marjanovic2, Monika S Kowalczyk2,3, Chao Wang1, Sema Kurtulus1, Travis Law2, Yasaman Etminan1, James Nevin1, Christopher D Buckley4, Patrick R Burkett1,5, Jason D Buenrostro2, Orit Rozenblatt-Rosen2, Ana C Anderson6,7, Aviv Regev8,9,10, Vijay K Kuchroo11,12.
Abstract
The expression of co-inhibitory receptors, such as CTLA-4 and PD-1, on effector T cells is a key mechanism for ensuring immune homeostasis. Dysregulated expression of co-inhibitory receptors on CD4+ T cells promotes autoimmunity, whereas sustained overexpression on CD8+ T cells promotes T cell dysfunction or exhaustion, leading to impaired ability to clear chronic viral infections and diseases such as cancer1,2. Here, using RNA and protein expression profiling at single-cell resolution in mouse cells, we identify a module of co-inhibitory receptors that includes not only several known co-inhibitory receptors (PD-1, TIM-3, LAG-3 and TIGIT) but also many new surface receptors. We functionally validated two new co-inhibitory receptors, activated protein C receptor (PROCR) and podoplanin (PDPN). The module of co-inhibitory receptors is co-expressed in both CD4+ and CD8+ T cells and is part of a larger co-inhibitory gene program that is shared by non-responsive T cells in several physiological contexts and is driven by the immunoregulatory cytokine IL-27. Computational analysis identified the transcription factors PRDM1 and c-MAF as cooperative regulators of the co-inhibitory module, and this was validated experimentally. This molecular circuit underlies the co-expression of co-inhibitory receptors in T cells and identifies regulators of T cell function with the potential to control autoimmunity and tumour immunity.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29899446 PMCID: PMC6130914 DOI: 10.1038/s41586-018-0206-z
Source DB: PubMed Journal: Nature ISSN: 0028-0836 Impact factor: 49.962
Figure 1.Multiple co-inhibitory receptors are expressed as a module on CD4+ and CD8+ T cells
a) CD4+ and CD8+ tumor-infiltrating lymphocytes (TILs) were harvested from WT mice bearing B16F10 melanoma tumors. Top panels, co-expression analysis of co-inhibitory and co-stimulatory receptor mRNA expression as determined by single-cell RNA-seq for 316 CD4+ and 588 CD8+ TILs. Bottom panels, protein expression by CyTOF for 23,656 CD4+ and 36,486 CD8+ TILs. Spearman correlation, followed by dendrogram ordering of the matrix using Euclidian distance is shown. Data are from biologically independent experiments. b) TILs from WT mice bearing B16F10 melanoma were analyzed using CyTOF with a custom panel of antibodies against co-inhibitory and co-stimulatory cell surface receptors[2,24] (). Data were analyzed using vi-SNE. Polygons indicating clusters 1, 2 (in CD8+ T cells), 3 and 4 (in CD4+ T cells) are shown. Individual panels show expression of the indicated markers. c) Naïve T cells from either wild type (WT) or IL-27ra deficient (IL27ra KO) mice were stimulated with anti-CD3/CD28 in the presence or absence of IL-27. Indicated co-inhibitory receptors expression was examined by real-time PCR (qPCR) at 96hr (CD4) and 72hr (CD8). Data are from biologically independent animals. mean + s.e.m is shown. d) vi-SNE plot showing WT (red) and IL27ra KO (blue) cells. e) ScRNA-seq of TILs from mice bearing B16F10 melanoma. Data were analyzed using t-SNE. Polygons indicating cluster 4 (in CD4+ T cells, orange) and cluster 5 (in CD8+ T cells, blue) are shown. Individual panels show expression of the indicated markers. Bar graphs show the mean signal intensity for indicated co-inhibitory receptors from WT (CD4+ (n=849); CD8+ (n=1752)) and IL27ra KO (CD4+ (n=628); CD8+ (n=541)) TILs for CyTOF (d) or WT (CD4+ (n=707); CD8+ (n=825)) and IL27ra KO (CD4+ (n=376); CD8+ (n=394)) TILs for ScRNA-seq (e). Error bars indicate s.e.m. and *p < 0.05, **p < 0.01, ***p < 0.001; two-sided t-test.